 This study will evaluate the pharmacokinetics PK, safety, and efficacy of emtricitabinetenofovir alafenamide FTAF in HIV-1 infected children and adolescents virologically suppressed defined as having 50 copiesmL of HIV-1 RNA for a period of at least 6 months while on a stable 2-nucleosidenucleotide reverse transcriptase inhibitor NRTI containing regimen. 